These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 37615708)

  • 1. Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.
    Wahi A; Jain P; Sinhari A; Jadhav HR
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):675-702. PubMed ID: 37615708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
    Singh AK; Bishayee A; Pandey AK
    Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
    Hanikoglu A; Hanikoglu F; Ozben T
    Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterocyclic Moieties as HDAC Inhibitors: Role in Cancer Therapeutics.
    Tasneem S; Alam MM; Amir M; Akhter M; Parvez S; Verma G; Nainwal LM; Equbal A; Anwer T; Shaquiquzzaman M
    Mini Rev Med Chem; 2022; 22(12):1648-1706. PubMed ID: 34939540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC Inhibitors.
    Olzscha H; Bekheet ME; Sheikh S; La Thangue NB
    Methods Mol Biol; 2016; 1436():281-303. PubMed ID: 27246222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antineoplastic activity of plant-derived compounds mediated through inhibition of histone deacetylase: a review.
    Rajaselvi ND; Jida MD; Ajeeshkumar KK; Nair SN; John P; Aziz Z; Nisha AR
    Amino Acids; 2023 Dec; 55(12):1803-1817. PubMed ID: 37389730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Overview of HDAC Inhibitors and their Synthetic Routes.
    Peng X; Liao G; Sun P; Yu Z; Chen J
    Curr Top Med Chem; 2019; 19(12):1005-1040. PubMed ID: 30827245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in histone deacetylase targeted cancer therapy.
    Hoshino I; Matsubara H
    Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural products as zinc-dependent histone deacetylase inhibitors.
    Tan S; Liu ZP
    ChemMedChem; 2015 Mar; 10(3):441-50. PubMed ID: 25581683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural Agents-Mediated Targeting of Histone Deacetylases.
    Farooqi AA; Naqvi SK; Perk AA; Yanar O; Tabassum S; Ahmad MS; Mansoor Q; Ashry MS; Ismail M; Naoum GE; Arafat WO
    Arch Immunol Ther Exp (Warsz); 2018 Feb; 66(1):31-44. PubMed ID: 28852775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDACs as an emerging target in endocrine tumors: a comprehensive review.
    Klieser E; Neumayer B; Di Fazio P; Mayr C; Neureiter D; Kiesslich T
    Expert Rev Endocrinol Metab; 2023 Mar; 18(2):143-154. PubMed ID: 36872882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.
    Peng X; Sun Z; Kuang P; Chen J
    Eur J Med Chem; 2020 Dec; 208():112831. PubMed ID: 32961382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging roles of HDACs and their therapeutic implications in cancer.
    Hai R; Yang D; Zheng F; Wang W; Han X; Bode AM; Luo X
    Eur J Pharmacol; 2022 Sep; 931():175216. PubMed ID: 35988787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases.
    Christianson DW
    Acc Chem Res; 2024 Apr; 57(8):1135-1148. PubMed ID: 38530703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.
    Qiu X; Zhu L; Wang H; Tan Y; Yang Z; Yang L; Wan L
    Bioorg Med Chem; 2021 Dec; 52():116510. PubMed ID: 34826681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC inhibitor-based therapies: can we interpret the code?
    New M; Olzscha H; La Thangue NB
    Mol Oncol; 2012 Dec; 6(6):637-56. PubMed ID: 23141799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.
    Mottamal M; Zheng S; Huang TL; Wang G
    Molecules; 2015 Mar; 20(3):3898-941. PubMed ID: 25738536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of naturally occurring histone deacetylase inhibitors.
    Kim B; Hong J
    Curr Top Med Chem; 2015; 14(24):2759-82. PubMed ID: 25487010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylases as targets in autoimmune and autoinflammatory diseases.
    Hamminger P; Rica R; Ellmeier W
    Adv Immunol; 2020; 147():1-59. PubMed ID: 32981634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.